Ovarian cancer ranks fifth in cancer deaths among U.S. women. According to American Cancer Society estimates, in 2021, more than 21,000 people were diagnosed with ovarian cancer, and nearly 14,000 people died from the disease. Ovarian cancer mostly develops in older people; approximately half of those diagnosed are age 63 or older. A person’s risk of getting ovarian cancer in their lifetime is about one in 78.
When identified and treated at an early stage, the five-year survival rate is approximately 94 percent. Unfortunately, most ovarian cancers are not identified until at an advanced stage, when they are more difficult to treat. Multiple factors make early diagnosis a challenge, including a lack of symptoms in the early stages and the fact that symptoms may not appear to be specific to a cancer diagnosis. Additionally, there is currently no reliable screening test for ovarian cancer.
In 2019, ACCC launched a multi-phase initiative aimed at improving care for patients with advanced epithelial ovarian cancer. The first phase, “Barriers to Quality Care in Ovarian Cancer,” focused on identifying existing barriers to treating patients with advanced ovarian cancer, determining the appropriate use and timing of guideline-concordant biomarker testing, and accessing solutions to optimize the diagnosis and treatment of patients.
In January 2022, ACCC launched the second phase in this effort: Advanced Ovarian Cancer Care Delivery. Since then, ACCC and its partner organizations—the Association for Molecular Pathology, the National Society of Genetic Counselors, and the Society of Gynecologic Oncology—have been conducting a quality initiative to identify and provide guidance on key issues related to the optimal care of patients diagnosed with advanced epithelial ovarian cancer across different practice settings. In addition to these goals, the project aims to:
For more information on this project, please contact the ACCC Provider Education department.
View this on-demand recording to explore the impact of ACCC’s quality improvement initiative on several ovarian cancer care programs and learn about the ovarian quality of care self-assessment tool.
Now available on-demand: Watch the recording of a recently live webinar to review key highlights learned during prior phases of an ovarian cancer care quality improvement initiative.
Premal H. Thanker, MD, MS, et al.
More than 20,000 women are diagnosed with ovarian cancer each year in the United States, most with advanced stage disease. With five year cause-specific survival of 47 percent, ovarian cancer is the fifth leading cause of cancer death among women in the United States. However, outcomes vary significantly by tumor stage, histologic type, and socio-demographic factors. Disparities in outcomes may be attributable to many factors, including sub-optimal quality of care. In the United States, fewer than one-third of patients with this disease currently receive guideline-concordant care. Recent advancements in curative intent therapeutic options for patients with ovarian cancer put a renewed emphasis on the need for high-quality care delivery.
Presented at the 2021 ASCO Quality Care Symposium, September 24 - 25, 2021.
Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations
Nov 17, 2021
The American Cancer Society Journal, Cancer. Download PDF.
Dr. Thaker on the Importance of Surveying Patients on Unmet Needs in Ovarian Cancer.
OncLive, Dec 2, 2021
ACCC Launches Quality-of-Care Improvement Initiative for Ovarian Cancer
Journal of Clinical Pathways
SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer
Society of Gynecologic Oncology, Oct 1, 2014